Research and Development Manufacture of mAb114 for Ebola

The contract numbered 75A50119C00059 was awarded to Ridgeback Biotherapeutics as a Letter contract for the research and development manufacture of mAb114, a monoclonal antibody treatment for Ebola. This award was made under a justification for other than full and open competition based on FAR 6.302-2, which addresses unusual and compelling urgency. The contract was issued by the Administration for Strategic Preparedness and Response within the Department of Health and Human Services and falls under the NAICS code 541714, which pertains to research and development in the physical, engineering, and life sciences. The contract posting occurred on December 3, 2019, and the work is performed in Miami, Florida. The special notice included a redacted Justification and Approval document required by FAR 6.305(b) to support the non-competitive award decision due to the urgent public health threat posed by Ebola. The specified point of contact for this contract is Ethan Mueller from the Department of Health and Human Services, who can be reached via email. This procurement highlights the government's expedited actions to address a pressing health emergency through targeted research and development partnerships.